Hepatic Ischemia-Reperfusion Injury
Conditions
Interventions
Trial group: taVNS group:taVNS group: Stimulation of the left auricular concha (the primary distribution area of the vagus nerve). Timing and duration of stimulation: 20 minutes after anesthesia induc
intensity 3 mA
duty cycle (on/off ratio) 30 s : 30 s.
Control group: Sham-taVNS group:Sham-taVNS group: The stimulation site, timing, and duration are identical to those of the active taVNS group
however, the stimulation is replaced with sham stimulation, consisting only of a brief transient stimulus at the beginning and end of each scheduled stimulation period.
Sponsors
First Affiliated Hospital, Army Medical University, Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 59 years; 2. Preoperative anesthetic assessment with ASA physical status classification I–III; 3. Normal or well-preserved preoperative liver function (Child-Pugh class A); 4. Undergoing open or laparoscopic partial hepatectomy for benign or malignant hepatic tumors, with at least one period of Pringle maneuver lasting >=15 minutes during surgery; 5. No prior anti-tumor treatments such as portal vein embolization (PVE), transarterial chemoembolization (TACE), or systemic anti-tumor therapy; 6. Anesthesia method is general anesthesia; 7. Patients have fully understood the study content, voluntarily participated, and provided signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Presence of one or more of the following preoperative cardiac, pulmonary, or renal dysfunctions: (1)NYHA cardiac function classification >= III; conduction block and/or severe ventricular dysfunction; (2)Preoperative coexisting COPD, asthma, and/or pulmonary infection; SaO2 <= 90% at rest while breathing ambient air; (3)eGFR <= 60 ml/min; requiring intermittent renal dialysis. 2. Pregnant or lactating women; 3. Patients with biliary tract disease (e.g., stones, obstruction, infection); 4. Preoperative imaging reveals extrahepatic disease requiring synchronous resection of organs other than the gallbladder; 5. Patients with epilepsy, cognitive impairment, or inability to cooperate; 6. Contraindications to taVNS (e.g., implanted cardiac pacemaker, cochlear implant, or other electronic devices); 7. Patients taking anticholinergic medications preoperatively; 8. Dermatological lesions on the left ear region; 9. Patients planned for left internal jugular vein catheterization; 10. Patients already enrolled in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak ALT Level Within 72 Hours Postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| Renal Function;Arterial Blood Gas;Postoperative Length of Stay and Total Length of Stay;Inflammatory Response Markers;Incidence of Other Adverse Events Within 3 Days Postoperatively;Complete Blood Count;Coagulation Function;Liver function (e.g., alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, etc.); | — |
Countries
China
Contacts
Public ContactGu Jianteng
First Affiliated Hospital, Army Medical University, Chinese People's Liberation Army
Outcome results
None listed